144 related articles for article (PubMed ID: 20677921)
1. Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study.
Hamidieh AA; Hamedani R; Hadjibabaie M; Amini M; Sadrai S; Ghavamzadeh A
Pediatr Hematol Oncol; 2010 Oct; 27(7):529-33. PubMed ID: 20677921
[TBL] [Abstract][Full Text] [Related]
2. Lorazepam for seizure prophylaxis during high-dose busulfan administration.
Chan KW; Mullen CA; Worth LL; Choroszy M; Koontz S; Tran H; Slopis J
Bone Marrow Transplant; 2002 Jun; 29(12):963-5. PubMed ID: 12098063
[TBL] [Abstract][Full Text] [Related]
3. Outdated dogma? Busulfan, seizure prophylaxis, and stem cell allografting.
Ruiz-Argüelles GJ; Gomez-Almaguer D; Steensma DP
Am J Hematol; 2012 Sep; 87(9):941. PubMed ID: 22674687
[No Abstract] [Full Text] [Related]
4. Continuous intravenous infusion of lorazepam as seizure prophylaxis in children treated with high-dose busulfan.
Caselli D; Ziino O; Bartoli A; Santangelo G; Vanadia F; Aricò M
Bone Marrow Transplant; 2008 Jul; 42(2):135-6. PubMed ID: 18372906
[No Abstract] [Full Text] [Related]
5. Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation.
Soni S; Skeens M; Termuhlen AM; Bajwa RP; Gross TG; Pai V
Pediatr Blood Cancer; 2012 Oct; 59(4):762-4. PubMed ID: 22378696
[TBL] [Abstract][Full Text] [Related]
6. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.
Small TN; Young JW; Castro-Malaspina H; Prockop S; Wilton A; Heller G; Boulad F; Chiu M; Hsu K; Jakubowski A; Kernan NA; Perales MA; O'Reilly RJ; Papadopoulos EB
Biol Blood Marrow Transplant; 2007 Feb; 13(2):235-44. PubMed ID: 17241929
[TBL] [Abstract][Full Text] [Related]
7. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
Bartelink IH; Bredius RG; Ververs TT; Raphael MF; van Kesteren C; Bierings M; Rademaker CM; den Hartigh J; Uiterwaal CS; Zwaveling J; Boelens JJ
Biol Blood Marrow Transplant; 2008 Jan; 14(1):88-98. PubMed ID: 18158965
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic cell transplantation in acute lymphoblastic leukemia: better long term event-free survival with conditioning regimens containing total body irradiation.
Granados E; de La Cámara R; Madero L; Díaz MA; Martín-Regueira P; Steegmann JL; Arranz R; Figuera A; Fernández-Rañada JM
Haematologica; 2000 Oct; 85(10):1060-7. PubMed ID: 11025598
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation.
Tran H; Petropoulos D; Worth L; Mullen CA; Madden T; Andersson B; Choroszy M; Nguyen J; Webb SK; Chan KW
Biol Blood Marrow Transplant; 2004 Nov; 10(11):805-12. PubMed ID: 15505611
[TBL] [Abstract][Full Text] [Related]
10. [Peripheral blood hematopoietic cell transplant using immunosuppressive chemotherapy without bone marrow destruction: "minitransplant"].
Gómez-Almaguer D; Ruiz-Argüelles GJ; González-Llano O; Ruiz-Argüelles A; Cantú-Rodríguez OG
Gac Med Mex; 2002; 138(3):235-9. PubMed ID: 12096391
[TBL] [Abstract][Full Text] [Related]
11. Optimal prevention of seizures induced by high-dose busulfan.
Eberly AL; Anderson GD; Bubalo JS; McCune JS
Pharmacotherapy; 2008 Dec; 28(12):1502-10. PubMed ID: 19025431
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation.
Kletzel M; Jacobsohn D; Duerst R
Biol Blood Marrow Transplant; 2006 Apr; 12(4):472-9. PubMed ID: 16545731
[TBL] [Abstract][Full Text] [Related]
13. Limitations of oral busulfan in preparative regimen before hematopoietic stem-cell transplantation.
Kami M; Hamaki T; Maruta Y; Miyakoshi S; Mutou Y
Haematologica; 2002 Feb; 87(2):ELT10. PubMed ID: 11836187
[No Abstract] [Full Text] [Related]
14. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
Tran HT; Madden T; Petropoulos D; Worth LL; Felix EA; Sprigg-Saenz HA; Choroszy M; Danielson M; Przepiorka D; Chan KW
Bone Marrow Transplant; 2000 Sep; 26(5):463-70. PubMed ID: 11019834
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.
Worth L; Tran H; Petropoulos D; Culbert S; Mullen C; Roberts W; Przepiorka D; Chan K
Bone Marrow Transplant; 1999 Nov; 24(9):947-52. PubMed ID: 10556952
[TBL] [Abstract][Full Text] [Related]
16. Home administration of high-dose oral busulfan in patients undergoing hematopoietic stem cell transplantation.
Matthews RH; Emami M; Connaghan DG; Holland HK; Morris LE
Bone Marrow Transplant; 2007 Apr; 39(7):397-400. PubMed ID: 17322933
[TBL] [Abstract][Full Text] [Related]
17. [Allogeneic hematopoietic transplantation with stem cells extracted from peripheral blood].
Kusminsky G; Foncuberta MC; Aversa L; Drelichman G; Freigeiro D; Burgos R; Irrazabal C; Gonzalez G; Dictar M; Niborski R; Kohan A; Sanchez Avalos JC
Medicina (B Aires); 2000; 60(2):179-87. PubMed ID: 10962806
[TBL] [Abstract][Full Text] [Related]
18. Pretransplant conditioning in adults and children: dose assurance with intravenous busulfan.
Fisher VL; Barnes YJ; Nuss SL
Oncol Nurs Forum; 2006 Nov; 33(2):E36-43. PubMed ID: 16518436
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
Saito T; Kanda Y; Kami M; Kato K; Shoji N; Kanai S; Ohnishi T; Kawano Y; Nakai K; Ogasawara T; Matsubara H; Makimoto A; Tanosaki R; Tobinai K; Wakasugi H; Takaue Y; Mineishi S
Clin Cancer Res; 2002 Apr; 8(4):1014-20. PubMed ID: 11948108
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and tolerability of intravenous busulfan in hematopoietic stem cell transplantation.
Cho YH; Lim HA; Lee MH; Kim I; Lee JS; Park Sy; Kim BK; Yoon SS
Clin Transplant; 2007; 21(3):417-22. PubMed ID: 17488395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
